Noble Financial Predicts Ocugen's Q2 Earnings (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Stock analysts at Noble Financial upped their Q2 2025 earnings estimates for shares of Ocugen in a research note issued to investors on Monday, May 12th. Noble Financial analyst R. Leboyer now expects that the company will post earnings per share of ($0.06) for the quarter, up from their prior estimate of ($0.08). The consensus estimate for Ocugen's current full-year earnings is ($0.20) per share. Noble Financial also issued estimates for Ocugen's Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.24) EPS.

Ocugen (NASDAQ:OCGN - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The business had revenue of $1.48 million for the quarter. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%.

A number of other analysts have also recently weighed in on the stock. HC Wainwright lowered their price target on shares of Ocugen from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Monday. Chardan Capital reiterated a "buy" rating and issued a $7.00 target price on shares of Ocugen in a research note on Monday.

Ocugen Stock Up 0.4%

NASDAQ:OCGN opened at $0.70 on Wednesday. Ocugen has a fifty-two week low of $0.52 and a fifty-two week high of $2.06. The stock has a market capitalization of $205.15 million, a P/E ratio of -3.90 and a beta of 4.21. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. The company's 50-day simple moving average is $0.66 and its 200-day simple moving average is $0.76.

Institutional Trading of Ocugen

A number of institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new stake in Ocugen during the 4th quarter valued at approximately $30,000. Ameriprise Financial Inc. acquired a new stake in Ocugen during the 4th quarter valued at approximately $30,000. Virtu Financial LLC acquired a new stake in Ocugen during the 4th quarter valued at approximately $32,000. Tower Research Capital LLC TRC lifted its stake in Ocugen by 309.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company's stock valued at $32,000 after acquiring an additional 30,120 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new stake in Ocugen during the 4th quarter valued at approximately $40,000. 10.27% of the stock is currently owned by institutional investors and hedge funds.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.